Cell Culture Technology– category –
-
iPSC-Derived Scar Organoid (SCO) Model Established, Revolutionizing Human Hypertrophic Scar Pathogenesis and Antifibrotic Drug Screening
MDPI Switzerland Overview Researchers have successfully developed an iPSC-derived scar organoid (SCO) model that accurately recapitulates key features of human hypertrophic scars, including collagen accumulation and tissue contraction. T... -
STEMCELL Technologies Supports Organoid Research with Standardized hPSC Lines and Differentiation Kits
STEMCELL Technologies Canada Overview STEMCELL Technologies offers high-quality human iPSC lines and differentiation kits, including the STEMdiff™ Intestinal Organoid Kit, to support diverse research applications such as organoid generat... -
ACS Study: Novel Laminin-511 Inspired 3D Zwitterionic Hydrogel (PCB-LN511) Significantly Outperforms Matrigel in hPSC Culture
ACS Publications USA Overview A groundbreaking study published in ACS Publications reports the development of a novel 3D zwitterionic hydrogel, PCB-LN511, inspired by Laminin-511, for human pluripotent stem cell (hPSC) culture. This inno... -
Organoid Revolution: 3D Models Set New Standard for Drug Discovery and Development
学術論文 (UU.DIVA-PORTAL.ORG) スウェーデン Overview Organoids are rapidly transforming drug discovery and development, serving as miniature 3D tissue models that offer significantly enhanced physiological relevance compared to traditiona... -
VIVEbiotech Scales In Vivo Gene Therapy Portfolio to 15 Programs, Securing Key FDA Clinical Trial Approvals
PharmaSource スペイン Overview Spanish CDMO VIVEbiotech has significantly expanded its in vivo lentiviral vector gene therapy portfolio to 15 programs, several of which have already secured regulatory clearance for clinical trials, inclu... -
Biomanufacturing Quality Control Transforms with Real-time PAT and AI Integration Under FDA ICH Q13 Guidance
Technology Networks UK Overview Process Analytical Technology (PAT) in biomanufacturing is undergoing a paradigm shift from endpoint testing to real-time, in-line measurement, driven by FDA's ICH Q13 guidance on continuous manufacturing,... -
Strategic CDMO Partnerships Accelerate in Cell and Gene Therapy Market to Tackle Manufacturing and Cost Challenges
Contract Pharma USA Overview The burgeoning cell and gene therapy (CGT) market is increasingly relying on strategic CDMO partnerships to navigate complex manufacturing and cost challenges. Sponsors are actively seeking CDMOs with special... -
CellShip® Method Preserves iPSC-Derived Cardiac Organoids for 7 Days at Room Temperature, Outperforming Cryopreservation
MDPI Switzerland Overview A novel room-temperature preservation method using CellShip® has successfully maintained the viability and functionality of human iPSC-derived cardiac organoids for up to seven days, significantly surpassing the... -
Heartseed Doses First Patient in Phase I/II EMERALD Study with iPSC-Derived Cardiomyocyte Spheroids HS-005 for Severe Heart Failure; Nikon CeLL innovation Provides Manufacturing Support
Heartseed Japan Overview Heartseed announced the successful dosing of the first patient in its Phase I/II EMERALD study for HS-005, an iPSC-derived cell therapy for severe heart failure. HS-005 consists of cardiomyocyte spheroids manufac... -
Century Therapeutics Unveils CNTY-813 iPSC-Derived Islet Replacement Preclinical Data at ADA 2026: Demonstrates Durable Glucose Control, Immune Evasion, and Scalable Manufacturing, IND Filing Expected Q4 2026
BioSpace (via GlobeNewswire) USA Overview Century Therapeutics presented new preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, at the ADA 2026 Scientific Sessions. The data demonstrated durable glucose control, i...
